Descripción del proyecto
Potenciar el cribado durante el descubrimiento de fármacos impulsará el éxito de este proceso
Los fármacos todavía tardan unos catorce años en recibir su aprobación y la tasa de fracaso durante los ensayos clínicos se sitúa en torno al 85 %. En cada fase, muchos candidatos fracasan debido a problemas de seguridad y eficacia, en gran medida porque los modelos de investigación de la enfermedad no representan de manera adecuada todos los factores humanos. SINERGIA se centrará en optimizar el uso de cuatro tecnologías de vanguardia que apoyan el modelado «in vivo» de los mecanismos y efectos de los fármacos. El proyecto reúne a entidades académicas de investigación, organizaciones de investigación por contrato y empresas biotecnológicas y farmacéuticas. La aplicación de unos mejores modelos de enfermedad en el proceso de descubrimiento de fármacos podría aumentar de manera significativa el éxito y la velocidad con la que los candidatos a fármacos pasan de la investigación a su administración a pacientes.
Objetivo
A key step in the drug development process is to predict information on safety, efficacy and mechanisms of action of a candidate molecule as early as possible in the pipeline (drug screening). To accomplish this aim, physiological and pathological pre-clinical models that closely approximate the human body are required. The limited capabilities of most of the existing pre-clinical screening tools, unable to meet the physiological relevance required to screen out failing drug candidates, reflect in the current weak performances of drug discovery: high attrition rates indeed affect the process of taking drugs from lab to market. Despite emerging new technologies exist with potential for advancing the field of in vitro modelling, their successfully implementation in the drug discovery pipeline to make it more efficient is still challenging. This is also imputable to a lack of structured dialogue between academic technology providers, market-oriented and regulatory-aware CROs, Biotechs and Pharma companies, which finally affects the research, training and development pipeline. SINERGIA aims at integrating a training network where academic and non-academic actors contribute to unravel the potential of the synergistic and rational use of four key bioengineering technologies. In particular, SINERGIA features academic leading experts of i) organs-on-chip and microfabrication technologies; ii) bioreactor and tissue engineering; iii) 3D Bioprinting; iv) induced-pluripotent human stem cells. These techniques are deployed to CROs and Biotech Consortium members that will ensure rational development, exploitation, validation and compliancy with regulatory and industrial aspects. Ultimately, this concerted action will lead to advanced models of human physiology and diseases to be introduced in preclinical stages of an innovative and improved drug discovery pipeline.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicinephysiology
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
20133 Milano
Italia